Rhythm Biosciences Ltd (ASX: RHY) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Rhythm Biosciences Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$22.88 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
245.98 million
Earnings per share
-0.039
Dividend per share
N/A
Year To Date Return
-29.63%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Rhythm Biosciences Ltd (ASX: RHY)
Latest News
Share Market News
What is going on with the Rhythm (ASX:RHY) share price today?
Share Market News
The Rhythm (ASX:RHY) share price surges on cancer testing milestone
Share Market News
Which ASX healthcare shares saw the biggest gains in February?
Share Market News
What's happening with the Rhythm (ASX:RHY) share price today?
Share Market News
Why the Rhythm (ASX:RHY) share price again reached a new all-time record today
Share Market News
Here's why the Rhythm (ASX:RHY) share price hit an all-time high today
Share Market News
Rhythm Biosciences (ASX: RHY) share price soars 1300% in 6 months
Share Gainers
Here's why the Rhythm Bioscience (ASX:RHY) share price is up 15% to a record high
Share Market News
Why the Rhythm Biosciences (ASX:RHY) share price jumped over 600% this year
Share Market News
The Rhythm (ASX:RHY) share price is surging 5% higher today. Here's why.
Share Gainers
Why the Rhythm Biosciences (ASX:RHY) share price rocketed 28% to a record high
Share Gainers
These small cap ASX shares delivered more than 100% returns in November
RHY ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Rhythm Biosciences Ltd
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. Geographically, the company operates only in Australia.
RHY Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 19 Apr 2024 | $0.09 | $0.00 | 0.00% | 12,164 | $0.09 | $0.09 | $0.09 |
| 18 Apr 2024 | $0.09 | $0.00 | 0.00% | 25,211 | $0.09 | $0.09 | $0.09 |
| 17 Apr 2024 | $0.09 | $0.00 | 0.00% | 97,946 | $0.09 | $0.09 | $0.09 |
| 16 Apr 2024 | $0.09 | $0.00 | 0.00% | 141,899 | $0.09 | $0.09 | $0.09 |
| 15 Apr 2024 | $0.09 | $0.00 | 0.00% | 96,967 | $0.09 | $0.09 | $0.09 |
| 12 Apr 2024 | $0.09 | $0.00 | 0.00% | 54,165 | $0.09 | $0.09 | $0.09 |
| 11 Apr 2024 | $0.09 | $0.00 | 0.00% | 137,258 | $0.09 | $0.10 | $0.09 |
| 10 Apr 2024 | $0.10 | $0.00 | 0.00% | 135,807 | $0.09 | $0.10 | $0.09 |
| 09 Apr 2024 | $0.09 | $0.00 | 0.00% | 54,352 | $0.09 | $0.09 | $0.09 |
| 08 Apr 2024 | $0.09 | $0.00 | 0.00% | 92,015 | $0.09 | $0.09 | $0.09 |
| 05 Apr 2024 | $0.09 | $0.00 | 0.00% | 94,272 | $0.09 | $0.10 | $0.09 |
| 04 Apr 2024 | $0.10 | $0.00 | 0.00% | 87,218 | $0.09 | $0.10 | $0.09 |
| 03 Apr 2024 | $0.09 | $0.00 | 0.00% | 21,033 | $0.09 | $0.09 | $0.09 |
| 02 Apr 2024 | $0.10 | $0.00 | 0.00% | 379,710 | $0.10 | $0.10 | $0.09 |
| 28 Mar 2024 | $0.10 | $0.00 | 0.00% | 81,002 | $0.09 | $0.10 | $0.09 |
| 27 Mar 2024 | $0.09 | $0.00 | 0.00% | 810 | $0.09 | $0.09 | $0.09 |
| 26 Mar 2024 | $0.09 | $0.00 | 0.00% | 52,098 | $0.09 | $0.09 | $0.09 |
| 25 Mar 2024 | $0.09 | $0.00 | 0.00% | 56,567 | $0.09 | $0.09 | $0.09 |
| 22 Mar 2024 | $0.09 | $-0.01 | -10.00% | 198,436 | $0.10 | $0.10 | $0.09 |
| 21 Mar 2024 | $0.10 | $0.00 | 0.00% | 69,241 | $0.10 | $0.10 | $0.10 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 21 Mar 2024 | Otto Buttula | Issued | 5,425,001 | $542,500 |
Rights issue.
|
| 21 Mar 2024 | Otto Buttula | Issued | 10,850,000 | $1,085,000 |
Rights issue.
|
| 21 Mar 2024 | Louis (Lou) Panaccio | Issued | 124,500 | $12,450 |
Rights issue.
|
| 21 Mar 2024 | Louis (Lou) Panaccio | Issued | 249,000 | $24,900 |
Rights issue.
|
| 21 Mar 2024 | Trevor Lockett | Issued | 387,300 | $38,730 |
Rights issue.
|
| 21 Mar 2024 | Trevor Lockett | Issued | 193,650 | $19,365 |
Rights issue.
|
| 10 Oct 2023 | Sue(Susan) MacLeman | Issued | 200,000 | $61,000 |
Issue of options.
|
| 08 Aug 2023 | Trevor Lockett | Exercise | 1,125,000 | $225,000 |
Exercise of options.
|
| 08 Aug 2023 | Trevor Lockett | Buy | 1,125,000 | $225,000 |
Exercise of options.
|
| 30 Jun 2023 | Trevor Lockett | Expiry | 125,000 | $51,250 |
Options expired.
|
| 30 Jun 2023 | Louis (Lou) Panaccio | Expiry | 37,500 | $15,375 |
Options expired.
|
| 30 Jun 2023 | Otto Buttula | Expiry | 500,000 | $205,000 |
Options expired.
|
| 12 May 2023 | Otto Buttula | Buy | 683,895 | $248,245 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Otto Leslie Steven Buttula | Executive ChairmanExecutive Director | Oct 2019 |
Mr Buttula has had experience in investment research, funds management, information and biotechnologies and has held directorships in a number of public companies. Mr Buttula founded and was Managing Director of Investors Mutual, prior to which he was a co-founder and director of Lonsdale Securities Ltd. He is a Director of HITIQ Limited (appointed 28 January 2021) and OncoSil Medical Limited (appointed 20 July 2021).
|
| Mr Louis (Lou) James Panaccio | Non-Executive Director | Aug 2017 |
Mr Panaccio has management experience in business and healthcare services. Mr Panaccio is also on the board of Unison Housing Ltd. Mr Panaccio has more than twenty years experience as a board member of both public and private, for profit and not for profit companies. Previously, Mr Panaccio was the CEO of Melbourne Pathology and Monash IVF, and executive Chairman of Health Networks Australia.
|
| Ms Sue(Susan) MacLeman | Non-Executive Director | Jan 2023 |
Mr MacLeman has more than 30 years experience as a pharmaceutical, biotechnology and medical technology executive having held senior roles in corporate, medical, commercial and business development at Schering Plough Corporation (now Merck), Amgen, Bristol Myers Squibb and Mesoblast. Sue has also served as CEO and a Board member of several ASX, AIM and NASDAQ listed companies in the Healthtech sector. Sue is currently the Chair of the Medical Technologies and Pharmaceuticals Growth Centre (MTPConnect). Sue is a Non Executive Director of Planet Innovation Holdings Ltd, ATSE and OMICO (Australian Genomic Cancer Medicines Ltd). Sue is also appointed to several academic and government advisory boards. Sue brings a unique set of experiences in technology commercialisation, strategic planning, capital markets and fund raising, M&A and alliance management.
|
| Dr Trevor John Lockett | Non-Executive Director | Nov 2018 |
Dr Lockett has postdoctoral experience at the Rockefeller University in New York. With over 30 years of research experience, predominantly at the CSIRO, Dr Lockett has led research efforts in the areas of prostate cancer gene therapy, colorectal cancer prevention and the promotion of gastrointestinal health. In his role as Theme Leader, Colorectal Cancer and Gut Health, Dr Lockett oversaw the research efforts which led to the technology that is to become ColoSTAT.
|
| Ms Andrea Steele | Company SecretaryGeneral Counsel | Feb 2022 |
-
|
| Mr James Stephen Barrie | Joint Company Secretary | Dec 2023 |
-
|
| Andrea Steele | Company SecretaryGeneral Counsel |
-
|
|
| James Stephen Barrie | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Webinvest Pty Ltd | 17,291,667 | 7.83% |
| Ferndale Securities Pty Ltd | 10,300,000 | 4.66% |
| Loumea Investment Pty Ltd | 8,052,520 | 3.65% |
| Northern Star Nominees Pty Ltd | 7,380,000 | 3.34% |
| Newfound Investments Pty Ltd | 6,819,729 | 3.09% |
| HSBC Custody Nominees (Australia) Limited | 6,515,269 | 2.95% |
| Rojo Nero Capital Pty Ltd | 4,323,751 | 1.96% |
| Giokir Pty Ltd | 3,661,470 | 1.66% |
| Mr Hsien Michael Soo | 3,305,403 | 1.50% |
| Commonwealth Scientific & Industrial Research Organisation | 2,500,000 | 1.13% |
| Ms Natalie Louise Patterson | 2,477,083 | 1.12% |
| E & W Nominee Pty Ltd | 2,207,941 | 1.00% |
| Mr Daniel Eddington & Mrs Julie Eddington | 2,123,532 | 0.96% |
| Mr Mark Anthony Rogers & Mr Arthur Nicholas Veliss | 2,000,000 | 0.91% |
| Mrs Sarah Cameron | 1,920,800 | 0.87% |
| Jawaf Enterprises Pty Ltd | 1,875,000 | 0.85% |
| BNP Paribas Nominees Pty Ltd Acf Clearstream | 1,662,733 | 0.75% |
| Mrs Joan Margaret Molyneux & Mrs Wendy Anne Hutchison & Mr John Edward Hutchison | 1,450,000 | 0.66% |
| Mr Richard Stanley De Ravin | 1,448,228 | 0.66% |
| Mr Adrian Darby | 1,357,124 | 0.61% |
